Why did MTVA's EPS remain flat in recent quarters?

The EPS of MetaVia (MTVA) remained flat in recent quarters due to a combination of factors:

1. Financial Performance Challenges: MetaVia reported a full-year loss of $27.59 million, with an EPS of -$3.56, compared to the previous year's loss of $12.47 million and an EPS of -$2.46. This indicates a decline in profitability over the past year.
2. Revenue Challenges: The company reported an estimated revenue of $0.00 million for the current quarter, indicating a complete lack of revenue generation. This is a significant concern for a company's financial health and contributes to the flat EPS trend.
3. Cash Position: MetaVia's cash reserves stood at $16.0 million at the end of the fourth quarter, expected to fund operations into the third quarter of 2025. This limited cash position could restrict the company's ability to invest in growth opportunities or reduce expenses, which might be contributing to the flat EPS.
4. Strategic Developments: The company has been focusing on strategic realignment and clinical developments, as seen with the positive results from the Phase 2a trial of DA-1241. While these developments are positive, they may not have an immediate impact on EPS due to the ongoing nature of clinical trials and the need for further development and regulatory approvals.

In summary, MetaVia's flat EPS in recent quarters can be attributed to a combination of financial performance challenges, lack of revenue, limited cash position, and strategic developments. These factors collectively contribute to the company's current financial situation.